rofecoxib
Sign in to saveRofecoxib is a COX-2-selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. Rofecoxib was approved in the United States by the Food and Drug Administration (FDA) in May 1999, and was marketed under the brand names Vioxx, Ceoxx, and Ceeoxx. Rofecoxib was available by prescription in both tablets and as an oral suspension.
Key facts
- Drug.verifiedrevid
- 470623576
- Drug.IUPAC_name
- 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one
- Drug.image
- Rofecoxib.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 170px
- Drug.image2
- Rofecoxib-3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Vioxx, Ceoxx, Ceeoxx, others
- Drug.pregnancy_AU
- C
- Drug.legal_status
- withdrawn worldwide
- Drug.routes_of_administration
- By mouth & i.m
- Drug.bioavailability
- 93%
- Drug.protein_bound
- 87%
- Drug.metabolism
- liver
- Drug.elimination_half life
- 17 hours
- Drug.excretion
- bile duct/kidney
- Drug.IUPHAR_ligand
- 2893
- Drug.CAS_number
- 162011-90-7
via Wikipedia infobox
Article
22 sectionsContents
- Mode of action
- Pharmacokinetics
- Efficacy
- Premenstrual acne
- Fabricated efficacy studies
- Side effects
- Heart and blood vessels
- VIGOR study and publishing controversy
- Alzheimer's disease
- APPROVe study
- Other studies
- Other COX-2 inhibitors
- Other NSAIDs
- Withdrawal
- Martin Report
- FDA position
- Litigation
- Possible return to market
- See also
- Footnotes
- References
- External links
Rofecoxib is a COX-2-selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. Rofecoxib was approved in the United States by the Food and Drug Administration (FDA) in May 1999, and was marketed under the brand names Vioxx, Ceoxx, and Ceeoxx. Rofecoxib was available by prescription in both tablets and as an oral suspension.
Rofecoxib gained widespread use among physicians treating patients with arthritis and other conditions causing chronic or acute pain. Worldwide, over 80 million people were prescribed rofecoxib at some time.